Innate Pharma S.A. (IPHA)
IPHANASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$1.54
+0.0099 (+0.65%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.52 –
- Market cap
- $169.78m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.46 to $1.55
- 52-week range
- $1.17 to $2.71
- Average volume
- 35.9k
- Previous close
- $1.53
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $6.67, +333.1% from here
Earnings
Next report
Financials
No quarterly figures from the source.
News
8 latest- Innate Pharma S.A. Reports Third Quarter 2026 Business and Financial UpdateFintel · 5 days ago
- Innate Pharma Q3 Earnings Call HighlightsMarketBeat · 5 days ago
- Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027Fintel · Oct 27, 2026
- Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround Zacks · Oct 8, 2026
- Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)Zacks · Oct 5, 2026
- Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22Fintel · Oct 2, 2026
- Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should KnowZacks · Sep 23, 2026
- Innate Pharma (IPHA) Q2 2026 Earnings Call TranscriptThe Motley Fool · Sep 17, 2026
The company
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- innate-pharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.